Literature DB >> 1807823

Treatment of polymyalgia rheumatica/giant cell arteritis.

V Kyle.   

Abstract

Corticosteroids control arteritis in GCA and suppress polymyalgic symptoms within days of starting treatment. PMR patients can be treated with approximately 15 mg prednisolone/day, reducing the dose to 7.5-10 mg by 8 weeks. GCA is normally controlled on 40 mg prednisolone/day, although patients with persistent visual symptoms may need 60-80 mg. Slow reduction to about 20 mg by 8 weeks should minimize relapses. For both PMR and GCA a maintenance dose of 7.5 mg after 6-9 months should be enough. Steroid withdrawal is possible within 2 years of starting treatment, although some will need 4 years or more. Relapse should be defined clinically; the ESR is the most useful laboratory parameter. Steroid side-effects can be minimized by using low doses of prednisolone whenever possible and azathioprine may be used as a steroid-sparing agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1807823     DOI: 10.1016/s0950-3579(05)80067-6

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  3 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.

Authors:  S Schreiber; M Buyse
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

3.  Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder.

Authors:  Muhammad Raza Cheema; Shakawan M Ismaeel
Journal:  Clin Interv Aging       Date:  2016-02-23       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.